Activation of poly(ADP-Ribose) polymerase contributes to development of doxorubicin-induced heart failure

P. Pacher, L. Liaudet, P. Bai, L. Virag, Jon Mabley, G. Hasko, C. Szabo

Research output: Contribution to journalArticleResearchpeer-review

Original languageEnglish
Pages (from-to)862-867
Number of pages6
JournalJournal of Pharmacology and Experimental Therapeutics
Volume300
Issue number3
DOIs
Publication statusPublished - Mar 2002

Cite this

Pacher, P. ; Liaudet, L. ; Bai, P. ; Virag, L. ; Mabley, Jon ; Hasko, G. ; Szabo, C. / Activation of poly(ADP-Ribose) polymerase contributes to development of doxorubicin-induced heart failure. In: Journal of Pharmacology and Experimental Therapeutics. 2002 ; Vol. 300, No. 3. pp. 862-867.
@article{8a2e3c2e439e4faab3febfd32f4fff2b,
title = "Activation of poly(ADP-Ribose) polymerase contributes to development of doxorubicin-induced heart failure",
author = "P. Pacher and L. Liaudet and P. Bai and L. Virag and Jon Mabley and G. Hasko and C. Szabo",
year = "2002",
month = "3",
doi = "10.1124/jpet.300.3.862",
language = "English",
volume = "300",
pages = "862--867",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
number = "3",

}

Activation of poly(ADP-Ribose) polymerase contributes to development of doxorubicin-induced heart failure. / Pacher, P.; Liaudet, L.; Bai, P.; Virag, L.; Mabley, Jon; Hasko, G.; Szabo, C.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 300, No. 3, 03.2002, p. 862-867.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Activation of poly(ADP-Ribose) polymerase contributes to development of doxorubicin-induced heart failure

AU - Pacher, P.

AU - Liaudet, L.

AU - Bai, P.

AU - Virag, L.

AU - Mabley, Jon

AU - Hasko, G.

AU - Szabo, C.

PY - 2002/3

Y1 - 2002/3

U2 - 10.1124/jpet.300.3.862

DO - 10.1124/jpet.300.3.862

M3 - Article

VL - 300

SP - 862

EP - 867

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -